Cencora, Inc. logo

Cencora, Inc.

COR

NYSEHealthcareMedical - Distribution

Previous close

$318.04

+$3.35 · +1.06%

Aug 21, 4:00 PM ET

COR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

91

Deep Value

Momentum

43

Neutral

Sentiment

60

Mixed

Risk resilience

77

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
US
CEO
Robert Mauch
Listed since
Apr 4, 1995
Employees
49,000

Market position

Day range

Current $318.04

52-week range

Current $318.04

Open
$314.74
Previous close
$314.69
Volume
622.91K
0.36× average
Average volume
1.71M
Average daily volume
Market cap
61.88B USD
Beta
0.57
Market reference 1
50-day average
$302.44
+5.16% above average
200-day average
$323.54
-1.70% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
66.93B USD
P/E (TTM)
23.52×
P/B (TTM)
20.13×
P/S (TTM)
0.19×
EV / EBITDA
17.91×
Earnings yield
2.57%
Free cash flow yield
5.29%
Dividend yield
0.75%

Profitability & efficiency

Gross margin
3.71%
Operating margin
1.30%
Net margin
0.79%
Return on equity
103.06%
Return on assets
2.03%
Return on invested capital
13.23%

Financial health

Debt / equity
3.84×
Current ratio
0.9×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3%2%1%0%Gross margin, FY2021: 2.93%Gross margin, FY2022: 3.19%Gross margin, FY2023: 2.96%Gross margin, FY2024: 2.96%Gross margin, FY2025: 3.16%Operating margin, FY2021: 1.25%Operating margin, FY2022: 1.15%Operating margin, FY2023: 0.93%Operating margin, FY2024: 1.03%Operating margin, FY2025: 1.14%Net margin, FY2021: 0.72%Net margin, FY2022: 0.71%Net margin, FY2023: 0.67%Net margin, FY2024: 0.51%Net margin, FY2025: 0.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 2.93%. Gross margin FY2022 3.19%. Gross margin FY2023 2.96%. Gross margin FY2024 2.96%. Gross margin FY2025 3.16%. Operating margin FY2021 1.25%. Operating margin FY2022 1.15%. Operating margin FY2023 0.93%. Operating margin FY2024 1.03%. Operating margin FY2025 1.14%. Net margin FY2021 0.72%. Net margin FY2022 0.71%. Net margin FY2023 0.67%. Net margin FY2024 0.51%. Net margin FY2025 0.48%.

Income trends

Revenue

321.33B USD+9.31%

Operating income

3.65B USD+19.98%

Net income

1.55B USD+2.99%
Income trends across reported periods353.32B USD225.39B USD97.46B USD−30.47B USDRevenue, FY2021: 213.99B USDRevenue, FY2022: 238.59B USDRevenue, FY2023: 262.17B USDRevenue, FY2024: 293.96B USDRevenue, FY2025: 321.33B USDOperating income, FY2021: 2.68B USDOperating income, FY2022: 2.75B USDOperating income, FY2023: 2.45B USDOperating income, FY2024: 3.04B USDOperating income, FY2025: 3.65B USDNet income, FY2021: 1.54B USDNet income, FY2022: 1.7B USDNet income, FY2023: 1.75B USDNet income, FY2024: 1.51B USDNet income, FY2025: 1.55B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 213.99B USD. Revenue FY2022 238.59B USD. Revenue FY2023 262.17B USD. Revenue FY2024 293.96B USD. Revenue FY2025 321.33B USD. Operating income FY2021 2.68B USD. Operating income FY2022 2.75B USD. Operating income FY2023 2.45B USD. Operating income FY2024 3.04B USD. Operating income FY2025 3.65B USD. Net income FY2021 1.54B USD. Net income FY2022 1.7B USD. Net income FY2023 1.75B USD. Net income FY2024 1.51B USD. Net income FY2025 1.55B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue321.33B USD293.96B USD262.17B USD238.59B USD213.99B USD
Cost of goods sold311.19B USD285.26B USD254.42B USD230.99B USD207.72B USD
Gross profit10.14B USD8.7B USD7.76B USD7.6B USD6.27B USD
Selling, general, and administrative6.49B USD5.66B USD5.31B USD4.85B USD3.59B USD
Operating expenses6.49B USD5.66B USD5.31B USD4.85B USD3.59B USD
Interest income128.21M USD91.69M USD46.72M USD21.31M USD8.47M USD
Interest expense419.75M USD248.68M USD275.65M USD231.98M USD182.54M USD
Depreciation and amortization1.06B USD1.11B USD972.39M USD697.94M USD505.17M USD
Operating income3.65B USD3.04B USD2.45B USD2.75B USD2.68B USD
Net income1.55B USD1.51B USD1.75B USD1.7B USD1.54B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+4.11%
11 comparable reports
Latest EPS result
4.48
Estimate 4.35 · Beat by 2.99%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates5.014.443.883.31Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 3.73, estimate 3.5, surprise +6.57%, Beat. Q2 2025, reported May 7, 2025: actual 4.42, estimate 4.11, surprise +7.54%, Beat. Q3 2025, reported Aug 6, 2025: actual 4, estimate 3.85, surprise +3.90%, Beat. Q4 2025, reported Nov 5, 2025: actual 3.84, estimate 3.79, surprise +1.32%, Beat. Q1 2026, reported Feb 4, 2026: actual 4.08, estimate 4.05, surprise +0.74%, Beat. Q2 2026, reported May 6, 2026: actual 4.75, estimate 4.82, surprise -1.45%, Miss. Q3 2026, reported Aug 5, 2026: actual 4.48, estimate 4.35, surprise +2.99%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 4.51, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates91.67B85.09B78.51B71.93BQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 81.49B USD, estimate 78.31B USD, surprise +4.06%, Beat. Q2 2025, reported May 7, 2025: actual 75.45B USD, estimate 75.68B USD, surprise -0.30%, Miss. Q3 2025, reported Aug 6, 2025: actual 80.66B USD, estimate 80.09B USD, surprise +0.71%, Beat. Q4 2025, reported Nov 5, 2025: actual 83.73B USD, estimate 83.46B USD, surprise +0.32%, Beat. Q1 2026, reported Feb 4, 2026: actual 85.93B USD, estimate 86.06B USD, surprise -0.15%, Miss. Q2 2026, reported May 6, 2026: actual 78.36B USD, estimate 81.09B USD, surprise -3.37%, Miss. Q3 2026, reported Aug 5, 2026: actual 84.75B USD, estimate 84.31B USD, surprise +0.52%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 88.14B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$358.14

12.61% upside
Past 12 months12-month forecastHigh $430Average $358.14Low $330

Rating distribution

46 ratings
Strong buy00%
Buy3372%
Hold1226%
Sell12%
Strong sell00%

Recent analyst actions

12 institutions

COR news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$2.25

2025 complete year-47.9% since 2021

2026 partial: $1.80

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Aug 14, 2026

$0.60

Quarterly

Record Aug 14, 2026 · Payment Aug 31, 2026

Dividend

Ex-dividend May 15, 2026

$0.60

Quarterly

Record May 15, 2026 · Payment Jun 1, 2026

Dividend

Ex-dividend Feb 13, 2026

$0.60

Quarterly

Record Feb 13, 2026 · Payment Mar 2, 2026

Dividend

Ex-dividend Nov 14, 2025

$0.60

Quarterly

Record Nov 14, 2025 · Payment Dec 1, 2025

Dividend

Ex-dividend Aug 15, 2025

$0.55

Quarterly

Record Aug 15, 2025 · Payment Sep 3, 2025

Dividend

Ex-dividend May 16, 2025

$0.55

Quarterly

Record May 16, 2025 · Payment Jun 2, 2025

COR peers

ETFs holding COR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research COR

research.disclaimer